NCT07797426
A Study of RT023 in Patients With Advanced Solid Tumors
StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Start date changed from estimate of Sep 12, 2026 to Sep 16, 2026
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
DLT
Timeframe: Up to 12 months
Adverse Events
Timeframe: Up to 36 months
MTD
Timeframe: Up to 12 months
RP2D
Timeframe: Up to 12 months
ORR
Timeframe: Up to 36 months
SAEs
Timeframe: Up to 36 months
Secondary (8)
DoR
DCR
PFS
OS
Cmax
Show 3 moreShow less
Immunogenicity
AUC0-t
t1/2
Arms and interventions
dose escalationExperimental
Participants with advanced solid tumors will receive escalating doses of RT023.
dose expansionExperimental
Participants with advanced solid tumors will receive RT023 at doses which are expected to be efficacious and have completed dose escalation.
clinical expansionExperimental
Participants with target tumors will receive RT023 at the Recommended Phase 2 dose (RP2D).
Drugs: RT023
Sites
1 site in 1 country
- Shanghai East HospitalShanghai, Shanghai Municipality, China